Morphocell Technologies Inc., a Montreal-based biotechnology company in the cell therapy space, recently announced the closure of a US$40 million Series A funding round. The funding is set to fuel the company’s groundbreaking journey towards a first-in-human clinical trial of the first cell therapy issued from its tissue engineering platform, aimed at transforming liver disease treatment globally.
Morphocell Technologies is an alumnus of our CAAP® program and presented at the OBIO® Investment Summit.